



Mailing Address:

Attn: Jen Laws
PO Box 3009
Slidell, LA 70459

Chief Executive Officer:

Jen Laws
Phone: (313) 333-8534
Fax: (646) 786-3825
Email: jen@tiicann.org

Board of Directors:

Darnell Lewis, Chair
Judith Montenegro, Secretary
Dusty Garner, Treasurer

Hon. Donna Christensen, MD
Patrick Ingram, MHSA
Riley Johnson
Kim Molnar
Judith Montenegro
Amanda Pratter

Director Emeritus:

William E. Arnold (*in Memoriam*)
Jeff Coudriet (*in Memoriam*)
Hon. Maurice Hinchey, MC (*in Memoriam*)
Gary R. Rose, JD (*in Memoriam*)
Kathie Heirs

National Programs:

340B Action Center
PDAB Action Center
Transgender Leadership in HIV Advocacy
HIV/HCV Co-Infection Watch

National Groups:

Hepatitis Education, Advocacy & Leadership
(HEAL) Group
Industry Advisory Group (IAG)
National ADAP Working Group (NAWG)

Community Access National Network Responds to HRSA's Revised 340B Rebate Model Pilot Program

WASHINGTON, DC (August 4, 2026) – Today, Jen Laws, President & CEO of Community Access National Network, released the following statement in response to Health Resources and Services Administration (HRSA) announcing the [revised 340B Rebate Model Pilot Program](#):

“The news of a refreshed 340B rebate pilot program is a respite to the unfortunate realities of egregious program growth and the problems that ensue, from lack of patient benefit to duplicate discounts. Recently, HRSA revealed that the 340B program expanded to more than \$100 billion in 2025, further calling compliancy, accountability and transparency into question. Not to say CANN is as prophetic as the Oracle of Delphi, but we have been sounding this alarm for quite some time.

“The pilot integrates information provided by CANN and other stakeholders from previous comment periods including how AIDS Drug Assistance Programs (ADAPs) have successfully functioned under a rebate model and payment timelines as a matter of practical application both in contracts and relative to other federal programs.

“Further, the pilot is modest in the data it seeks to collect, scope of affected medications for which a rebate may be mandated, and recognizes the costly nature of retrospective dispute and audit processes. HRSA's role in the pilot moves from passive and reactive engagement to more active oversight, requiring manufacturers to produce regular reports as to the function of the rebate model, will provide direct communication pathways for covered entities (including technical assistance), and the agency will actively seek feedback throughout the initial year pilot to better measure the scope and quality of impact.

“Opponents of the rebate model argue that retrospective reviews and audits are sufficient enough to warrant charging discounts upfront. But this assumes a level of transparency and accountability that is currently nonexistent. Instead, a rebate model incentivizes covered entity compliance as a prerequisite to receiving 340B discounts. Retrospective reviews, audits, and dispute resolution processes are inherently reactive, identifying potential duplicate discounts only after they have occurred.”